 BELTSVILLE, Md., Nov. 03, 2022 GLOBE NEWSWIRE -- NextCure, Inc. Nasdaq: NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that clinical trial investigator Nicholas Short, M.D., Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, will present a Trials in Progress poster for NC525, a novel first-in-class immunomedicine, at the American Society of Hematology ASH annual meeting in New Orleans. NC525 is a humanized monoclonal antibody that specifically binds to leukocyte-associated immunoglobulin-like receptor 1 LAIR-1 and is being developed for the treatment of advanced myeloid leukemia AML. 